Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancer types in the United States, with over 90% of tumors driven by oncogenic KRAS. Several KRAS inhibitors have demonstrated promising preclinical or early clinical efficacy; however, their therapeutic benefit is limited by the emergence of acquired...
Saurabh Mandal, M. Bharmal, Swathi Sridhar et al.· Cancer Research· 0 citations
The findings reveal distinct metastatic microenvironments in liver and lung characterized by coordinated differences in tumor subtype composition and myeloid phenotype, highlighting the importance of local immune landscapes in shaping metastatic disease biology.
E. Lasse-Opsahl, Daksh Thakkar, Julie M. Clark et al.· Cancer Research· 0 citations
The role of tumoral HMGA2 expression in controlling an immunosuppressive TME is demonstrated, a potential biomarker to determine TME phenotype in PDAC patients is highlighted and a novel subtype-specific immunomodulatory therapy is introduced.
Naomi Yamamoto, S. Dobersch, Tess M. Robertson et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.